Drug Price Trends for SYMPAZAN

Average Pharmacy Cost for SYMPAZAN

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
SYMPAZAN 5 MG FILM	10094-0205-60	16.14434	EACH	2025-04-01
SYMPAZAN 10 MG FILM	10094-0210-01	32.21612	EACH	2025-04-01
SYMPAZAN 20 MG FILM	10094-0220-01	64.46140	EACH	2025-04-01
SYMPAZAN 10 MG FILM	10094-0210-60	32.21612	EACH	2025-04-01
SYMPAZAN 5 MG FILM	10094-0205-01	16.14434	EACH	2025-04-01
SYMPAZAN 20 MG FILM	10094-0220-60	64.46140	EACH	2025-04-01

Market Analysis and Price Projections for Sympazan (Clobazam)

Overview of Sympazan

Sympazan, also known as clobazam, is a benzodiazepine derivative that acts as an anxiolytic, sedative, and anticonvulsant agent. It is specifically formulated as an oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older[1][3][5].

Market Demand and Growth

The demand for Sympazan is driven by the need for effective treatments for Lennox-Gastaut Syndrome, a severe form of epilepsy. The market for epilepsy treatments is growing, and Sympazan, with its unique oral film formulation, has carved out a niche for itself.

• Revenue Trends: Aquestive Therapeutics, the company behind Sympazan, has reported increasing revenues from royalty-based products, including Sympazan. In the third quarter of 2023, total revenues increased by 42% compared to the previous year, primarily driven by higher revenue from out-licensed products like Sympazan[4].
• Continued Contribution: In the third quarter of 2024, sales of royalty-based products, including Sympazan, continued to contribute to the company's revenue, although there was a slight decrease in manufacture and supply revenue due to various factors[5].

Pricing and Cost Analysis

The pricing of Sympazan is a critical factor in its market analysis.

• Current Pricing: The cost for Sympazan oral film varies by dosage. For example, a supply of 60 films of the 5 mg dosage costs around $1,042, while the 10 mg and 20 mg dosages cost approximately $2,074 and $4,140, respectively[2].
• Discount Programs: There are discount programs available, such as the Drugs.com Discount Card, which can save patients up to 80% off the cost of prescription medicines, including Sympazan[2].

Competitive Landscape

Sympazan operates in a competitive market for epilepsy treatments, but its unique formulation and delivery method set it apart.

• Unique Formulation: The oral film formulation of Sympazan provides an advantage over traditional tablets or capsules, especially for patients who have difficulty swallowing[3].
• Licensing Agreements: Aquestive Therapeutics has licensed Sympazan to Assertio Holdings, Inc., which has helped in expanding its market reach and growth opportunities[3].

Financial Projections

Based on recent financial reports and market trends, here are some key financial projections for Sympazan:

• Revenue Growth: Aquestive Therapeutics expects total revenue to be between $57 million and $60 million for the full year 2024, with a significant portion coming from license and royalty revenues, including those from Sympazan[5].
• Market Expansion: The company is focusing on expanding its manufacturing capabilities and supporting the growth of demand for existing and potential future licensed products, including Sympazan[5].

Challenges and Opportunities

Despite the growth potential, there are challenges and opportunities to consider:

• Regulatory Environment: Changes in regulatory environments and the approval process for new products can impact the market dynamics of Sympazan. For instance, overcoming orphan drug market exclusivity for certain age groups can be a challenge[4].
• Competition and Innovation: The epilepsy treatment market is highly competitive, and continuous innovation is necessary to maintain market share. Aquestive Therapeutics is investing in research and development to advance its product portfolio, including Sympazan[5].

Key Takeaways

• Growing Demand: The demand for effective epilepsy treatments, particularly for Lennox-Gastaut Syndrome, is driving the growth of Sympazan.
• Unique Formulation: The oral film formulation of Sympazan offers a competitive advantage.
• Financial Growth: Revenue from Sympazan is expected to contribute significantly to Aquestive Therapeutics' overall financial performance.
• Regulatory and Competitive Challenges: The company must navigate regulatory challenges and maintain innovation to stay competitive.

FAQs

1. What is Sympazan used for? Sympazan (clobazam) is used for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.

2. How is Sympazan administered? Sympazan is administered as an oral film, which is a unique formulation designed to be easy to use, especially for patients who have difficulty swallowing.

3. What are the current prices for Sympazan? The cost for Sympazan oral film varies by dosage, with a supply of 60 films of the 5 mg dosage costing around $1,042, the 10 mg dosage costing approximately $2,074, and the 20 mg dosage costing around $4,140.

4. Are there any discount programs available for Sympazan? Yes, there are discount programs available, such as the Drugs.com Discount Card, which can save patients up to 80% off the cost of prescription medicines, including Sympazan.

5. Who has licensed Sympazan for market distribution? Aquestive Therapeutics has licensed Sympazan to Assertio Holdings, Inc., which is responsible for its market distribution and sales.

Sources

1. GlobalData, "Net Present Value Model: Sympazan - GlobalData"
2. Drugs.com, "Sympazan Prices, Coupons, Copay Cards & Patient Assistance"
3. Aquestive Therapeutics, "Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc."
4. Aquestive Therapeutics, "Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update"
5. Aquestive Therapeutics, "Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update"